Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
- Resource Type
- Article
- Authors
- DiNardo, Courtney D.; Venugopal, Sangeetha; Lachowiez, Curtis; Takahashi, Koichi; Loghavi, Sanam; Montalban-Bravo, Guillermo; Wang, Xuemei; Carraway, Hetty; Sekeres, Mikkael; Sukkur, Ameenah; Hammond, Danielle; Chien, Kelly; Maiti, Abhishek; Masarova, Lucia; Sasaki, Koji; Alvarado, Yesid; Kadia, Tapan; Short, Nicholas J.; Daver, Naval; Borthakur, Gautam; Ravandi, Farhad; Kantarjian, Hagop M.; Patel, Bhumika; Dezern, Amy; Roboz, Gail; Garcia-Manero, Guillermo
- Source
- In Blood Advances 13 June 2023 7(11):2378-2387
- Subject
- Myeloid Neoplasia
- Language
- ISSN
- 2473-9529